RESEARCH ARTICLE

Cholesterol as a Risk Factor for Subarachnoid Hemorrhage: A Systematic Review

Joni Valdemar Lindbohm1,2*, Jaakko Kaprio1,3,4, Miikka Korja2

1 Department of Public Health, University of Helsinki, P.O. Box 41, FI-00014, Helsinki, Finland,
2 Department of Neurosurgery, University of Helsinki and Helsinki University Hospital, P.O. Box 266, FI-
00029, Helsinki, Finland, 3 National Institute for Health and Welfare, P.O. Box 30, FI-00271, Helsinki,
Finland, 4 Institute for Molecular Medicine FIMM, P.O. Box 20, FI-00014, Helsinki, Finland

* joni.lindbohm@helsinki.fi

Abstract

Background
The role played by total cholesterol (TC) in risk for subarachnoid hemorrhage (SAH) is unclear because studies report both high and low TC each as a risk factor. We performed a systematic review to clarify associations between lipid profile and SAH.

Methods
Our literature search comprised Pubmed, Scopus, and Cochrane Library databases with no language, publication year, or study type limitations. The Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) checklist guided our reporting. Data forms adapted from the Critical Appraisal Skills Program (CASP), and Cochrane Collaboration guidelines provided a platform for risk-of-bias evaluation. We used a random effects model to calculate pooled estimates and assessed heterogeneity with I²-statistics.

Results
Of the final 21 studies reviewed, 12 were prospective and 9 retrospective. All studies assessed TC, four assessed HDL, and none LDL in risk for SAH. Heterogeneity among all, retrospective, and Asian studies was high (I² = 79.5%, I² = 89.0%, and I² = 84.3%) and considerable in prospective (I² = 46.0%). We therefore focused on qualitative analysis and found that only two studies had a low risk of bias. According to these studies high TC increases risk for SAH in men, whereas the role of HDL remained unclear.

Conclusion
The low-risk-of-bias studies suggest that elevated TC levels elevate risk for SAH in men. Due to the high prevalence of hypercholesterolemia, population attributable risk (PAR) of hypercholesterolemia may exceed the PARs of smoking and hypertension in men. Apart from diabetes and obesity, the risk-factor profile of SAH seems to resemble that of other cerebrovascular diseases, at least in men.

Citation: Lindbohm JV, Kaprio J, Korja M (2016) Cholesterol as a Risk Factor for Subarachnoid Hemorrhage: A Systematic Review. PLoS ONE 11(4): e0152568. doi:10.1371/journal.pone.0152568

Editor: Terence J Quinn, University of Glasgow, UNITED KINGDOM

Received: January 25, 2016
Accepted: March 16, 2016
Published: April 14, 2016

Copyright: © 2016 Lindbohm et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are available in the paper and its Supporting Information files.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.
Introduction

Epidemiological studies of risk factors of subarachnoid hemorrhage (SAH) are challenging to conduct for a number of reasons, such as relatively young age at diagnosis, low overall incidence of disease, and high death-rate from the first bleed. The latter implies that outside-hospital deaths from SAH are comprehensively diagnosed only in countries with a high coverage of forensic autopsies for sudden deaths. The number of large, long-term, and population-based prospective studies on risk factors for SAH is limited.\cite{1-3} According to these studies, the most important risk factors for SAH are smoking, hypertension, female sex, and increasing age.\cite{1-3}

The role of total cholesterol (TC) in risk for SAH is conflicting, since studies report both high\cite{3-6} and low\cite{7-12} TC to raise risk. Meta-analyses\cite{13-15} suggest no association between TC and SAH, whereas they imply that high HDL is protective against SAH. The reviews do not include, however, a number of studies, such as a recent large study suggesting that high TC levels (>6.22 mmol/l) associate with future SAH in men.\cite{3} As blood lipid levels and especially high levels of low-density lipoprotein (LDL) are important risk factors for cardiovascular diseases in general,\cite{16} we reviewed current evidence on the role of TC and lipoproteins as risk factors for SAH. In contrast to the preceding reviews,\cite{13-15} ours also focuses in depth on methodological quality of the studies reviewed. Readers should note that M.K. and J.K. have published one of the studies reviewed.\cite{3}

Methods

Literature search

The protocol of this study is available in PROSPERO (International prospective register of systematic reviews, registration code: CRD42015016347) and follows the Preferred Reporting Items for Systematic reviews and Meta-analyses for Protocols Statement (PRISMA-P). The authors J.V.L. and M.K. did all steps of the protocol below; discussion with third-author J.K. resolved disagreements. We performed the literature search in two parts using Cochrane Library, Pubmed, and Scopus databases with no language limitations.\cite{S1 Methods}. We included non-English-language publications, native speakers assisted when necessary. We included all studies reporting effect estimates with a minimum of two categories for TC, LDL, HDL, or apolipoprotein concentrations. Depending on the design, we divided all studies into either prospective or retrospective to facilitate risk-of-bias evaluations. After reviewing risk-of-bias guidelines from the Cochrane Collaboration Handbook,\cite{17} Critical Appraisal Skills Program (CASP),\cite{18} Newcastle-Ottawa scale,\cite{19} and a measurement tool for assessment of multiple systematic reviews (AMSTAR)\cite{20} we based our risk-of-bias estimations to Cochrane Collaboration Handbook \cite{17} and CASP \cite{18}.

We used the PRISMA checklist\cite{21} as a guide to achieve the accepted standards for reporting systematic reviews. Based on the Cochrane Collaborations guidelines,\cite{17} we classified risk of bias into high, unclear, and low-grade categories. Our review focused especially on measurement bias, selection bias, reporting bias, confounder adjustment, reverse causality, and statistical power.

Statistical analysis

Based on the Cox proportional hazards model, we estimated sufficient sample size for prospective follow-up studies. We used a standard significance value of $p<0.05$, standard power value of $P = 0.8$, and incidence value of 20/100 000. For optimistic power analysis, we selected the hazard ratio (HR) 2.0 (95% CI 1.0–4.0) as effect size with a wide confidence interval and low
correlation factor value of 0.1 between covariates. We used a random effects model to calculate pooled estimates and assessed heterogeneity with I²-statistics. For two studies,[7,22] we inverted the reference category in order to present comparable results. Population attributable risk (PAR) was calculated with following formula: \( \text{PAR} = \frac{\pi f (R - 1)}{\pi f (R - 1) + 1} \), where \( \pi f \) is population fraction with hypercholesterolemia. Stata statistical software version 12.1 Stata Corp performed all the calculations.

**Results**

**General**

**Search results.** In brief, 21 studies[1–12,22–30] including ≥50 SAH cases emerged that reported associations between risk for SAH and TC levels “Fig 1”.

**Cohort characteristics.** Cohort sizes and follow-up times in prospective studies differed considerably, and the number of SAH ranged from 55[28] to 437[3] (Table 1). In the retrospective study, the number of SAHs ranged from 95[5] to 858.[9] The reported mean or median age at SAH in all studies ranged from 46.9[1] to 64[9] years (Table 1). Supplementary file “S1 Cohorts” describes the data collection in all 12 prospective studies in detail.

**Cases.** Eight prospective[1–3,6,8,22,29,30] and three[4,5,9] retrospective studies comprised both fatal and none-fatal SAHs. Five[1–3,6,29] prospective studies (all Finnish or Norwegian) also reported inclusion of outside hospital deaths (Table 1). Diagnosis-verification protocol (computed tomography or lumbar puncture) was sufficient in all studies.

**Total cholesterol**

**Associations in prospective studies.** Of the 12 studies,[1–3,6–8,22,24,27–30] two[7,8] suggested that low TC elevated risk for SAH (Table 2). The Swedish study observed, without having data on smoking, that low TC in men elevated SAH risk with a relative risk (RR) of 3.43 (Table 2).[7] The Japanese hospital-based cohort study reported that high TC lowered SAH risk with varying RRs 0.2 – 0.5 in low vs high analysis (no dose-response reported) including men and women with all their values above 4.14 mmol/l (Table 2).[8]

Two population-based studies,[3,6] including also outside hospital deaths, found that elevated TC levels (>5.59 mmol/l, >6.22 mmol/l, and >7.07 mmol/l vs ≤4.92 mmol/l[3] and ≥7.0 mmol/l vs <5.0 mmol/l[6]) increased risk for SAH in men with an HR of 1.97[3], 1.85[3], 2.18[3], and 1.79[6] (Table 2). The other study also reported dose response as a 1 mmol/l increase in TC raised risk for SAH in men with an HR of 1.16.[6] The remaining eight prospective studies[1,2,22,24,27–30] found no associations between TC and SAH (Table 2).

**Associations in retrospective studies.** Of the nine[4,5,9–12,23,25,26] studies, four[9–12] found that high TC measured by interview[10,12] or on admission (with hospital-based or health check-up control group),[9,11] decreased SAH risk with ORs of 0.2[12], 0.22[11], 0.41[10] and (in women only) 0.73 (Table 2).[9]

Three[4,5,25] studies with on-admission measurements found that elevated TC (≥4.9[5], ≥5.7[4], ≥6.3[24]) mmol/l elevated risk for SAH (ORs 1.02[5], 2.4[4], 15.7[24]) (Table 2). One of these studies also found an increased risk for SAH in women with high TC (≥5.7 mmol/l) with an RR of 4.08 (Table 2).[4] Two[4,25] of these three[4,5,25] used mainly healthy controls, and one[5] used other acute emergency room patients and their on-admission TC values (Table 2). Two[23,26] studies found no associations between TC and SAH (Table 2).

**TC range and power in prospective studies.** Nine studies[2,3,6,8,24,27–30] included a wide range of TC values, but only three[1,3,6] reported a sufficient sample size (≥31) of male and female SAHs in the high-TC group to determine an HR under 2 (Tables 2 and 3). Table 2 and “S1 Table” present TC measurement protocols in detail.
TC measurement and range in retrospective studies. Five [4,5,9,11,25] studies measured TC on admission after SAH and four [10,12,23,26] by interview. None of the nine [4,5,9–12,23,25,26] studies included a wide range of TC values in their analysis (Table 2).

Risk-factor adjustments in prospective studies. All [1–3,6,8,22,24,27–30] except one study [7] recorded known SAH risk factors: age, sex, hypertension, and smoking (or comprised only smokers or one sex), and all but two [2,7] controlled for them in a multivariable model. One study reporting high [6] and one low [8] TC as elevating risk for SAH also controlled for BMI values for confounding in analyses. The two studies reporting low TC as elevating risk lacked data on smoking [7] or analysis by sex [8].

Risk-factor adjustments in retrospective studies. All nine [4,5,9–12,23,25,26] studies recorded known risk factors for SAH, and the four [9–12] reporting low and the three [4,5,25] high TC as a risk factor for SAH controlled for them all.

Low-TC studies. Five retrospective [4,5,9–11] and three [8,22,27] prospective studies came from Japan and South Korea, where TC levels are generally lower than in Western countries. Separate analysis of these studies was still conflicting, since two [4,5] reported high and four [8–11] low TC as elevating risk, and two [22,27] remained inconclusive (Table 2).

Brief summary of TC findings. Of the 12 [1–3,6–8,22,24,27–30] prospective studies, 2 [3,6] found high TC raising risk for SAH in men. Conversely, two prospective studies found low TC as raising risk for SAH in men [7] and in both men and women [8] while eight [1,2,22,24,27–30] were indecisive (Table 2). Of the nine [4,5,9–12,23,25,26] retrospective studies, four [9–12] found low and three [4,5,25] high TC as raising risk for SAH whereas the others [23,26] remained inconsistent.
Table 1. Study characteristics. Summary of study characteristics and differences between prospective and retrospective studies.

| Authors and Country | Year | Size | Age | % of men | Median/mean Follow-up | SAH cases | Fatal or non-fatal SAHs included | Outside-hospital deaths included | Median/mean age at SAH |
|---------------------|------|------|-----|----------|-----------------------|-----------|---------------------------------|-------------------------------|-------------------------|
| **Prospective studies** |      |      |     |          |                       |           |                                 |                               |                         |
| Finland              |      |      |     |          |                       |           |                                 |                               |                         |
| Knekt [1]            | 1991 | 42   | 20–69 | 54 | 12 | 187 | Both | Yes | 46.9 |
| Korja [3]            | 2013 | 64   | 25–74 | 48.3 | 17.9 | 437 | Both | Yes | 59.3 |
| Leppälä [29]         | 1999 | 28   | 50–69 | 100 | 6  | 85  | Both | Yes | NR  |
| Zhang [6]            | 2012 | 58   | 25–74 | 47.6 | 20.1 | 332 | Both | Yes | NR  |
| Japan                |      |      |     |          |                       |           |                                 |                               |                         |
| Cui [27]             | 2007 | 38   | 40–79 | 38 | 10 | 66  | Fatal | NR  | 61.9 |
| Suzuki [8]           | 2011 | 156  | 30–89 | 48.7 | 3   | 223 | Both | No  | NR  |
| Norway               |      |      |     |          |                       |           |                                 |                               |                         |
| Sandvei [2]          | 2012 | 92   | 20–90+ | 33.6 | 10.9 | 122 | Both | Yes | 58.9 |
| South Korea          |      |      |     |          |                       |           |                                 |                               |                         |
| Suh [22]             | 2001 | 114  | 35–59 | 100 | 6   | 98  | Both | No  | NR  |
| Sweden               |      |      |     |          |                       |           |                                 |                               |                         |
| Gatchev [7]          | 1993 | 54   | 25–74 | 40.1 | 20.5 | 87  | Fatal | NR  | NR  |
| USA                  |      |      |     |          |                       |           |                                 |                               |                         |
| Iso [28] *           | 1989 | 350  | 35–57 | 100 | 6  | 55  | Fatal | No  | 47.4 |
| Neaton [24] *,†      | 1993 | 353  | 35–57 | 100 | 25 | 259 | Fatal | No  | 47.2 |
| Tirschwell [30]      | 2004 | 8010 | 30–79 | 44.2 | 11 | 96  | Both | NR  | N/A‡ |
| **Retrospective**    |      |      |     |          |                       |           |                                 |                               |                         |
| Great Britain & Denmark |    |      |     |          |                       |           |                                 |                               |                         |
| Adamson [25]         | 1994 | 189  | 25–70 | 44.8 | N/A | 96  | NR  | No  | 48  |
| Japan                |      |      |     |          |                       |           |                                 |                               |                         |
| Inagawa [4]          | 2005 | 494  | 25–96 | 43.7 | N/A | 247 | Both | No  | 62.6 |
| Inagawa [9]          | 2010 | 1941 | 31–89 | 35 | N/A | 858 | Both | NR  | 64  |
| Ohkuma [10]          | 2003 | 780  | 25–85< | 31 | N/A | 390 | NR  | No  | 58  |
| Tokuda [11]          | 2005 | 300  | 24–95 | 29 | N/A | 150 | NR  | No  | 60  |
| Holland              |      |      |     |          |                       |           |                                 |                               |                         |
| Vlak [12]            | 2013 | 824  | 54.8 (15.8)§ | 29 | N/A | 250 | Non-fatal | No  | 54.7 |
| Portugal             |      |      |     |          |                       |           |                                 |                               |                         |
| Canhao [26]          | 1994 | 423  | <40–65< | 30.5 | N/A | 141 | NR  | NR  | NR  |
| South Korea          |      |      |     |          |                       |           |                                 |                               |                         |
| Park [5]             | 1998 | 464  | 21–86 | 48.1 | N/A | 95  | Both | NR  | 51.7 |
| USA                  |      |      |     |          |                       |           |                                 |                               |                         |

(Continued)
Subfractions of cholesterol

**HDL and other lipoproteins.** Three[2,6,29] prospective and one[25] retrospective study analyzed associations between HDL and risk for SAH (Table 4). The one[25] retrospective also analyzed association of apolipoprotein B (ApoB) with SAH. None of the studies focused on any other lipoprotein subtypes, such as LDL, or the lipid subfractions nowadays available with lipidomic analyses.[31] S1 Table presents a detailed summary of different laboratory methods that studies used to analyze HDL.

**Associations.** One prospective study reported that risk for SAH decreased with an HR of 0.6 per SD unit increase in HDL in the subgroup under age 50 when they adjusted for age, sex, smoking, and alcohol consumption, but not for hypertension (Table 4).[2] Another prospective study controlled for known risk factors and also excluded participants who were using cholesterol-lowering medication.[6] After exclusion, however, the association between HDL and SAH remained unchanged. One study, comprising only male smokers, reported a decreasing risk for SAH with increasing HDL values (≥0.84 mmol/l) in their prospective setup (Table 4).[29] The only retrospective study focusing on lipoprotein subtypes used on-admission measurements, controlled for known risk factors for SAH, and found no significant associations between HDL, ApoB, and SAH [25](Table 4).

Risk of bias and power analyses

**Prospective studies.** Of the 12[1–3,6–8,22,24,27–30] studies, only 2[3,6] had a low risk of bias; those 2 had a sufficient number of SAHs, included outside hospital sudden deaths, comprehensive risk factor control, analysis by sex, wide TC range, unlikely selection bias, sufficient accuracy (validation) of diagnosis, unlikely measurement bias, and low risk for reverse causality “Fig 2”. In addition, although one[1] study met these criteria, all participants had very high TC levels; we thus determined that it had an unclear risk of bias. Nine studies[2,7,8,22,24,27–30] had a high risk of bias because of limitations in the aforementioned criteria “Fig 2”. Moreover, power calculations suggested that only three[1,3,6] studies were able to detect significant associations between high TC and SAH (Table 3).

**Retrospective and low-TC studies.** All nine[4,5,9–12,23,25,26] retrospective and eight[4,5,8–11,22,27] low-TC studies had a high risk of bias because of limitations in the aforementioned criteria “Fig 2”.

**Small studies.** Since small studies tend to combine SAH and intracranial hemorrhage in a group of hemorrhagic stroke, we excluded them from the analysis.

**Studies on HDL.** Of the four[2,6,25,29] studies, only one[6] had a low risk of bias, because it met the aforementioned criteria.
Table 2. Associations between TC and SAH. Associations between TC levels and SAH, number of SAHs in the subgroup analyses, and type of TC measurement with control group.

| Authors and country | Lowest vs highest or vice versa (mmol/l) | HR/RR/OR and 95% CIs | No. of SAHs among men | No. of male cases in highest category | No. of SAHs among women | No. of female cases in highest category | Cases’ TC measurement and type of cohort or control group |
|---------------------|-----------------------------------------|----------------------|-----------------------|--------------------------------------|------------------------|----------------------------------------|------------------------------------------------------|
| **Prospective**     |                                         |                      |                       |                                      |                        |                                        |                                                      |
| Finland             |                                         |                      |                       |                                      |                        |                                        |                                                      |
| Knekt [1]           | ≤5.96 vs 6.99<                          | M 0.9 (0.6–1.5) W 1.0 (0.6–1.8) | 102                   | 39                                   | 85                     | 39                                    | sB, PB                                               |
| Korja [3]           | <4.92 vs 7.07<                          | M 2.18 (1.19–4.00) W 0.99 (0.62–1.59) | 206                   | 58                                   | 231                    | 60                                    | sB, PB                                               |
| Leppälä [29]        | <4.90 vs 7.00<                          | 0.78 (0.38–1.62)     | 85                     | 19                                   | -                      | -                                     | B, MS                                                |
| Zhang [6]           | <5.00 vs 7.00<                          | M 1.79 (1.00–3.19) W 1.25 (0.71–2.20) | 151                   | 49                                   | 181                    | 46                                    | sB, PB                                               |
| **Japan**           |                                         |                      |                       |                                      |                        |                                        |                                                      |
| Cui [27]            | <4.14 vs 7.22<                          | 0.60 (0.08–4.73)     | 25                    | NR                                   | 41                     | NR                                    | nB, PB                                               |
| Suzuki [8]          | <4.14 vs 7.24<                          | 0.2 (0.0–0.8)        | 89                    | NR                                   | 134                    | NR                                    | B, H                                                |
| **Norway**          |                                         |                      |                       |                                      |                        |                                        |                                                      |
| Sandvei [2]         | 5.9, per SD (1.3)                       | 0.9 (0.7–1.1)        | 41                    | NR                                   | 81                     | NR                                    | nB, PB                                               |
| **South Korea**     |                                         |                      |                       |                                      |                        |                                        |                                                      |
| Suh [22] §          | <4.31 vs 5.70<                          | 0.69 (0.37–1.32)     | 98                    | 18                                   | -                      | -                                     | fB, CP                                               |
| **Sweden**          |                                         |                      |                       |                                      |                        |                                        |                                                      |
| Gatchev [7] §       | M 5.3 vs 7.6 W 5.4 vs 7.9              | M 0.29 (0.10–0.89) W 0.98 (0.42–2.08) | 37                    | 4                                    | 50                     | 12                                    | nB, PB                                               |
| **USA**             |                                         |                      |                       |                                      |                        |                                        |                                                      |
| Iso [28]            | <4.14 vs 7.24<                          | 0.16 *               | 55                    | 1                                    | -                      | -                                     | nB, IG                                               |
| Neaton [24]         | <4.14 vs 7.24<                          | 1.70 (0.76–3.83)     | 259                   | 17                                   | -                      | -                                     | nB, IG                                               |
| **Retrospective**   |                                         |                      |                       |                                      |                        |                                        |                                                      |
| Adamson [25]        | <5.40 vs 6.30<                          | 15.7 (2.8–89)        | 43                    | NR                                   | 53                     | NR                                    | aB, HE                                               |
| **Japan**           |                                         |                      |                       |                                      |                        |                                        |                                                      |
| Inagawa [4]         | <5.69 vs 5.69<                          | M 2.18 (0.67–7.08) W 4.08 (1.59–10.46) | 108                   | 18                                   | 139                    | 48                                    | aB, HE                                               |
| Inagawa [9]         | <5.69 vs 5.69<                          | M 0.89 (0.50–1.60) W 0.73 (0.55–0.98) | 276                   | NR                                   | 522                    | NR                                    | aB, HC                                               |
| Ohkuma [10]         | NR                                      | 0.41 (0.24–0.71)     | 119                   | NR                                   | 271                    | NR                                    | I, HE                                                |
| Tokuda [11]         | <5.20 vs 5.20<                          | 0.22 (0.12–0.40)     | 43                    | NR                                   | 107                    | NR                                    | aB, H                                                |
| **Holland**         |                                         |                      |                       |                                      |                        |                                        |                                                      |
| Vlak [12]           | NR                                      | 0.2 (0.1–0.4)        | 62                    | NR                                   | 188                    | NR                                    | I, HC                                                |
| **Portugal**        |                                         |                      |                       |                                      |                        |                                        |                                                      |

(Continued)
Meta-analysis. In addition to evident methodological differences among studies “Fig 2”, our meta-analysis showed also considerable heterogeneity. Heterogeneity among retrospective and Asian studies was high (I² = 79.5%-89.0%), and considerable in prospective studies (I² = 46.0%) "Figures A-D in S1 Figures”. Indisputably, meta-analysis on reviewed studies lacks justification. However, we performed a series of sensitivity analyses and selected the most similar studies for meta-analysis.

A meta-analysis limited to prospective studies with comparable wide TC groups, major limitations only in an analysis by sex and exclusion of certain SAH types,[3,24,27,30] showed moderate evidence that high TC elevates SAH risk with an RR of 1.33 "Figure E in S1 Figures”.

Table 3. Sample sizes. Required number of person-years and SAHs for subgroup analysis for different HR values.

| HR | SAH in subgroup studied | Person years needed |
|----|-------------------------|---------------------|
| 1.5 | 91                      | 452 854             |
| 1.6 | 68                      | 337 026             |
| 1.7 | 53                      | 264 414             |
| 1.8 | 44                      | 215 490             |
| 1.9 | 37                      | 180 715             |
| 2.0 | 31                      | 154 958             |
| 2.1 | 28                      | 135 248             |
| 2.2 | 24                      | 119 760             |
| 2.3 | 22                      | 107 318             |
| 2.4 | 20                      | 97 137              |
| 2.5 | 18                      | 88 675              |
| 2.6 | 17                      | 81 545              |
| 2.7 | 16                      | 75 466              |
| 2.8 | 15                      | 70 229              |

p<0.05, P = 0.8, covariate correlation factor 0.1, and incidence 20/100 000

doi:10.1371/journal.pone.0152568.t003
The meta-analysis including only retrospective studies with TC values measured in an acute phase[9,11,25] showed no association between TC and SAH. Figure F in S1 Figures. Meta-analysis including only studies which obtained TC values using interviews[10,12,26] showed low TC as risk factor (RR 0.42) Figure G in S1 Figures. The sensitivity analysis included a small number of studies, and has unreliable heterogeneity estimates.

Discussion

Some relatively high-quality evidence[3,6] suggests that high TC is a risk factor for SAH in men questioning the current understanding of SAH epidemiology. The role of HDL remained unresolved. [6] Only one[25] retrospective study focused on associations between ApoB and SAH, but found none, whereas none studied LDL. Meta-analyses[13–15] did not find strong associations between SAH and TC. However, they did not include extensive risk-of-bias analyses and, therefore may have failed to uncover sources of heterogeneity in the studies included.

Internal quality of SAH risk factor studies varies considerably, as most have significant methodological shortages and gaps in reporting. Five studies[3–6,25] reported high TC, six[7–12] low TC, and ten others[1,2,22–24,26–30] neither one as increasing risk for SAH. Of all 12 [1–3,6–8,22,24,27–30] prospective studies, 3[1,3,6] had sufficient statistical power to detect associations between high TC and SAH. Of all 21 studies,[1–12,22–30] only 2[3,6] had a low risk of bias. According to the classical Hills criteria of causality,[32] the two studies also had convincing temporality, biological gradient, plausibility, coherence, and analogy. These studies also included outside hospital SAH deaths. Both originated from the FINNRISK cohort but from different study groups. The most recent[3] included more SAH cases and found stronger

| Authors and Country | Protective factor | Highest vs lowest (mmol/l) | HR/RR/OR and 95% CIs | No. of SAHs among men | No. of male cases in lowest category | No. of SAHs among women | No. of female cases in lowest category | Cases’ TC measurement and type of controls or cohort |
|---------------------|-------------------|---------------------------|----------------------|-----------------------|-----------------------------------|------------------------|----------------------------------|--------------------------------------------------|
| **Prospective**      |                    |                           |                      |                       |                                   |                        |                                  |                                                  |
| Finland             | High HDL           | 1.45 vs <0.84             | 0.26 (0.11–0.62)     | 85                    | 14                                | 0                      | 0                                | B, SM                                            |
| Zhang [6]           | None               | <1.0 vs 1.4               | M 0.56 (0.25–1.25) W 1.27 (0.50–3.28) | 151            | 17                                | 181                    | 15                               | sB, PB                                            |
| Norway              |                    |                           |                      |                       |                                   |                        |                                  |                                                  |
| Sandvei [2]         | None               | 1.4 (SD 0.4)              | 1.0 (0.9–1.3)        | 41                    | NR                                | 81                     | NR                               | nB, PB                                            |
| <50 years           | High HDL           | 1.4 (SD 0.4)              | 0.6 (0.4–0.9)        | NR                    | NR                                | NR                     | NR                               |                                                  |
| >50 years           | Low HDL            | 1.4 (SD 0.4)              | 1.2 (1.0–1.5)        | NR                    | NR                                | NR                     | NR                               |                                                  |
| **Retrospective**   |                    |                           |                      |                       |                                   |                        |                                  |                                                  |
| Great Britain & Denmark |                |                           |                      |                       |                                   |                        |                                  |                                                  |
| Adamson [25]        | None               | 1.4 vs <1.1               | NR                   | 43                    | NR                                | 53                     | NR                               | aB, HE                                            |
| ApoB (g/l)          | None               | 0.83 vs <0.65             | 1.0 CIs NR           | 43                    | NR                                | 53                     | NR                               |                                                  |

M = men, W = women, B = unknown blood sample, aB = on admission blood sample, nB = non-fasting blood sample, sB = semi-fasting blood sample, HE = healthy controls, PB = population based cohort, SM = cohort of male smokers, NR = not reported

* per SD increase

doi:10.1371/journal.pone.0152568.t004

The meta-analysis including only retrospective studies with TC values measured in an acute phase[9,11,25] showed no association between TC and SAH "Figure F in S1 Figures". Meta-analysis including only studies which obtained TC values using interviews[10,12,26] showed low TC as risk factor (RR 0.42) "Figure G in S1 Figures". The sensitivity analysis included a small number of studies, and has unreliable heterogeneity estimates.
associations between elevated TC and SAH. Also sensitivity analysis including prospective studies (with comparable TC levels and only few limitations) supported the view that elevated TC associates with SAH risk. As TC is a well-known risk factor for cardiovascular diseases in general, [16] and atherosclerotic changes are commonly found in aneurysm walls, [33] the results for TC seem reasonable. Analysis of low-TC studies separately provided no support for the hypothesis of a U-shaped risk curve.

The recent low-risk-of-bias study suggested [3] that TC levels over 5.6mmol/l elevate risk of SAH with HR of approximately 2 in men. Based on the varying prevalence (between 17% and 55%) of hypercholesterolemia worldwide, [34] the HR of 2 in men translates into PAR estimates ranging from 17% to 35%. The PAR of hypercholesterolemia in men can reach up to 35% in Europe, and up to 32% in the USA. Because TC levels are increasing in a number of countries, [35] PAR of hypercholesterolemia is likely to increase especially in developing countries. The recent low-risk-of-bias study reported HRs of 2.53 and 1.23 for smoking and hypertension in men. [3] With a prevalence estimate of 25% for smoking and 41% for hypertension, the HRs translate into PARs of 28% and 9% in men. Thus, TC may significantly contribute to the SAH incidence among men, and to the difference in risk-factor profiles between sexes.

TC and LDL levels are well-documented risk factors for other cardiovascular diseases (CVDs), whereas HDL is generally considered a protective risk indicator. [16] The role of a high LDL is considered to be causal, whereas the causal nature of the HDL association has been questioned. [36–38] Furthermore, the influence of these factors on CVDs may differ by sex [39,40] because premenopausal women are also at lower risk for CVDs than are age-matched men. [16] Physiological changes during menopause elevate risk for CVDs, [41] when TC and

---

**Fig 2. Risk of bias.** Classification of risk of bias and sources of bias in all studies.

doi:10.1371/journal.pone.0152568.g002

---

The recent low-risk-of-bias study suggested that TC levels over 5.6mmol/l elevate risk of SAH with HR of approximately 2 in men. Based on the varying prevalence (between 17% and 55%) of hypercholesterolemia worldwide, the HR of 2 in men translates into PAR estimates ranging from 17% to 35%. The PAR of hypercholesterolemia in men can reach up to 35% in Europe, and up to 32% in the USA. Because TC levels are increasing in a number of countries, PAR of hypercholesterolemia is likely to increase especially in developing countries. The recent low-risk-of-bias study reported HRs of 2.53 and 1.23 for smoking and hypertension in men. With a prevalence estimate of 25% for smoking and 41% for hypertension, the HRs translate into PARs of 28% and 9% in men. Thus, TC may significantly contribute to the SAH incidence among men, and to the difference in risk-factor profiles between sexes.

TC and LDL levels are well-documented risk factors for other cardiovascular diseases (CVDs), whereas HDL is generally considered a protective risk indicator. The role of a high LDL is considered to be causal, whereas the causal nature of the HDL association has been questioned. Furthermore, the influence of these factors on CVDs may differ by sex because premenopausal women are also at lower risk for CVDs than are age-matched men. Physiological changes during menopause elevate risk for CVDs, when TC and
LDL levels start to rise at its beginning and reach their peak at approximately age 60.[39] At the same time, HDL decreases and triglycerides increase, making the lipid profile more unfavorable, thus elevating risk for CVDs, especially in women.[39] Of those included, two[3,8] prospective studies reporting age-group SAH incidences, further stratified by sex, showed SAH incidence in women to surpass male incidence at age 65 and above. TC levels often being low in premenopausal women may in part explain why associations between TC and SAH are difficult to discover. This emphasizes the importance of analyzing and representing TC associations by sex and age and indicates that future SAH studies should focus on the role of TC in both pre- and postmenopausal women separately.

Prospective follow-up studies require a significant number (approx. 270 000) of person-years and optimally over 35 SAHs for each sex per TC subgroup to reliably study associations between TC levels and risk for SAH. In addition, because roughly 20% of SAH patients die away from hospitals or in emergency rooms.[42] and are thus excluded from most studies, even more person-years may be necessary. Only four[1,3,6,29] Finnish and one Norwegian [2] population-based studies reported in their analyses inclusion of sudden deaths. Furthermore, TC values should be analyzed as a continuous variable and should include adequate numbers of participants with TC below 5.0 mmol/l and above 6.5 mmol/l. As the median age at SAH is nowadays 60 years,[2,3] the study cohort should be of a rather high median age with a very long follow-up. Even then, reliable studies on TC are nowadays very challenging to conduct, as a high proportion of those with hypercholesterolemia use statins. A recent retrospective study [43] relying on administrative data suggested that statin use in elderly patients with unruptured intracranial aneurysms does not affect the incidence rate of SAH. However, the study did not report TC levels at baseline or after statin treatment, and did not stratify the results by sex. All these factors considered, it is clear that discovering the epidemiological role of TC in SAH is challenging; relatively small and short-term studies need cautious interpretation.

One of the most important shortcomings in the prospective cohort studies reviewed is their lack of longitudinal follow-up data; changes in risk-factor profile during the study period may therefore distort and confound association analyses. For example, in prospective studies from Norway[2] and Finland,[3,6] TC levels were measured 6 (mean) and 12 (median) years before SAH. As TC values have been a target of intensive drug and diet therapies during recent decades,[16] it is likely that baseline values had changed during follow-ups. Indeed, since the 1970s, when the study surveys began, the decline in TC of the Finnish population has been rapid,[44] and thus the risk estimates for TC levels may be unreliable. However, these modifications can only underestimate the role of high TC levels as a risk factor for SAH, making any associations between TC and SAH only decrease or disappear.

The reliability of retrospective studies in finding new risk factors for SAH is generally limited, not only because all outside hospital deaths are excluded from analyses, but also because of the evident risk of measurement bias when risk factors are measured by interview or after SAH. This was also evident in our sensitivity analyses, which included only on admission TC measurements or measurements by interview. Studies which measured TC by interview suggested that low TC elevates SAH risk. As TC levels may decrease during and after SAH,[45,46] all studies which measure TC on admission or within days after SAH are prone to reverse causality. This view is consistent with the results of the retrospective study[9] reporting TC as a risk factor for aneurysm formation but not for SAH. In addition, selection bias may weaken the generalizability of hospital-based studies by limiting the inclusion of patients with low TC in their control groups. Indeed, those retrospective studies[4,5,25] that reported high TC as leading to increased risk for SAH, used other emergency room patients or healthy people as control groups.
Our review has a few shortcomings. First, we may have missed some relevant publications due to indexing errors and limitations in the search strategy. Our search strategy, however, yielded 21 reviewed studies whereas the three earlier systematic reviews on this topic comprised only 7,[15] 6,[13] and 3[14] studies with over 50 SAH cases. Second, the review includes study by two authors (M.K. and J.K.), making it possible that unintentional conflict of interest has biased risk-of-bias estimations. We tried to avoid this with an established and public study protocol registered in the PROSPERO. Despite this, readers need to take this into consideration when evaluating the presented evidence. Third, a reliable meta-analysis, one which could have elucidated the role of TC in SAH, was impossible due to methodological differences and lack of the necessary additional data.

**Conclusion**

Elevated TC levels may elevate risk for SAH among men, and therefore lipid profile should perhaps be taken into account when assessing risk for SAH in men. No convincing evidence exist that low TC elevates risk for SAH. Apart from diabetes and obesity, the risk-factor profile of SAH resembles that of other CVDs, at least in men.

**Supporting Information**

S1 Cohorts. Description of cohorts used in prospective studies.

(SDOCX)

S1 Figures. Meta-analysis and sensitivity analyses.

(SDOCX)

S1 Methods. Search strategy and protocol.

(SDOCX)

S1 PRISMA Checklist.

(SDOC)

S1 Table. Cholesterol measurement protocols used in studies reviewed.

(SDOCX)

**Acknowledgments**

We appreciate James Neaton and Marie Sandvei’s providing additional information about their studies. We thank Jari Haukka and Marja-Lisa Lindbohm for critical revisions and Tiina Heino for advice in search protocol, and Carolyn Brimley Norris for language revision. We also thank Liang He, Teemu Hermunen, Joonas Kirsi, and Siamak Bidel for translations.

**Author Contributions**

Conceived and designed the experiments: JVL JK MK. Performed the experiments: JVL JK MK. Analyzed the data: JVL JK MK. Contributed reagents/materials/analysis tools: JVL JK MK. Wrote the paper: JVL JK MK. Did the literature search and the data collection: JVL MK.

**References**

1.  Knekt P, Reunanen A, Aho K, Heliovaara M, Rissanen A, Aromaa A, et al. Risk factors for subarachnoid hemorrhage in a longitudinal population study. J Clin Epidemiol 1991; 44(9):933–939. PMID: 1890435
2.  Sandvei MS, Lindekleiv H, Romundstad PR, Muller TB, Vatten LJ, Ingebrigtsen T, et al. Risk factors for aneurysmal subarachnoid hemorrhage—BMI and serum lipids: 11-year follow-up of the HUNT and the
3. Korja M, Silventoinen K, Laattikainen T, Jousilahti P, Salomaa V, Hernesniemi J, et al. Risk factors and their combined effects on the incidence rate of subarachnoid hemorrhage—a population-based cohort study. PLoS One 2013 Sep 9; 8(9):e73760. doi: 10.1371/journal.pone.0073760 PMID: 24040058

4. Inagawa T. Risk factors for aneurysmal subarachnoid hemorrhage in patients in Izumo City, Japan. J Neurosurg 2005 Jan; 102(1):60–67. PMID: 15658097

5. Park JK, Kim HJ, Chang SJ, Koh SB, Koh SY. Risk factors for hemorrhagic stroke in Wonju, Korea. Yonsei Med J 1998 Jun; 39(3):229–235. PMID: 9664827

6. Zhang Y, Tuomilehto J, Jousilahti P, Wang Y, Antikainen R, Hu G. Total and high-density lipoprotein cholesterol and stroke risk. Stroke 2012 Jul; 43(7):1768–1774. doi: 10.1161/STROKEAHA.111.646778 PMID: 22496337

7. Gatchev O, Rastam L, Lindberg G, Gullberg B, Eklund GA, Isacsson SO. Subarachnoid hemorrhage, cerebral hemorrhage, and serum cholesterol concentration in men and women. Ann Epidemiol 1993 Jul; 3(4):403–409. PMID: 21793808

8. Suzuki K, Izumi M, Sakamoto T, Hayashi M. Blood pressure and total cholesterol level are critical risks especially for hemorrhagic stroke in Aomori, Japan. Cerebrovasc Dis 2011; 31(1):100–106. doi: 10.1159/000321506 PMID: 21079399

9. Inagawa T. Risk factors for the formation and rupture of intracranial saccular aneurysms in Shimane, Japan. World Neurosurg 2010 Mar; 73(3):155–64; discussion e23. doi: 10.1016/j.surneu.2009.03.007 PMID: 20860953

10. Okhuma H, Tabata H, Suzuki S, Islam MS. Risk factors for aneurysmal subarachnoid hemorrhage in Aomori, Japan. Stroke 2003 Jan; 34(1):96–100. PMID: 12511757

11. Tokuda Y, Stein GH. Serum lipids as protective factors for subarachnoid hemorrhage. J Clin Neurosci 2005 Jun; 12(5):538–541. PMID: 15975790

12. Vlak MH, Rinkel GJ, Grebe PE, Greving JP, Algra A. Lifetime risks for aneurysmal subarachnoid haemorrhage: multivariable risk stratification. J Neurol Neurosurg Psychiatry 2013 Jun; 84(6):619–623. doi: 10.1136/jnnp-2012-303783 PMID: 23355806

13. Feigin VL, Rinkel GJ, Lawes CM, Algra A, Bennett DA, van Gijn J, et al. Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. Stroke 2005 Dec; 36(12):2773–2780. PMID: 16282541

14. Teunissen LL, Rinkel GJ, Algra A, van Gijn J. Risk factors for subarachnoid hemorrhage: a systematic review. Stroke 1996 Mar; 27(3):544–549. PMID: 8610327

15. Wang X, Dong Y, Qi X, Huang C, Hou L. Cholesterol Levels and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis. Stroke 2013 May 23.

16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec 17; 106 (25):3143–3421.

17. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org. Version 5.0.2 ed.; 2009.

18. Critical Appraisal Skills Programme (CASp). CASP Checklists (http://media.wix.com/ugd/ded87_e37a4ab637fe46a0869f9f977dacf134.pdf) Oxford CASP 2014.

19. Newcastle-Ottawa Scale (NOS). http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

20. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007 Feb 15; 7:10. PMID: 17302989

21. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009 Jul 21; 6(7):e1000097. doi: 10.1371/journal.pmed.1000097 PMID: 19621072

22. Suh I, Jee SH, Kim HC, Nam CM, Kim IS, Appel LJ. Low serum cholesterol and haemorrhagic stroke in men: Korea Medical Insurance Corporation Study. Lancet 2001 Mar 24; 357(9260):922–925. PMID: 11289349

23. Broderick JP, Viscoli CM, Brott T, Kernan WN, Brass LM, Feldmann E, et al. Major risk factors for aneurysmal subarachnoid hemorrhage in the young are modifiable. Stroke 2003 Jun; 34(6):1375–1381. PMID: 12764233
24. Neaton JD, Wentworth DN, Cutler J, Stamler J, Kuller L. Risk factors for death from different types of stroke. Multiple Risk Factor Intervention Trial Research Group. Ann Epidemiol 1993 Sep; 3(5):493–499. PMID: 8167825

25. Adamson J, Humphries SE, Ostergaard JR, Voldby B, Richards P, Powell JT. Are cerebral aneurysms atherosclerotic? Stroke 1994 May; 25(5):963–966. PMID: 8165691

26. Canhão P, Pinto AN, Ferro H, Ferro JM. Smoking and aneurysmal subarachnoid haemorrhage: a case-control study. J Cardiovasc Risk 1994 Aug; 2(2):155–158. PMID: 7606628

27. Cui R, Iso H, Toyoshima H, Date C, Yamamoto A, Kikuchi S, et al. Serum total cholesterol levels and risk of mortality from stroke and coronary heart disease in Japanese: the JACC study. Atherosclerosis 2007 Oct; 194(2):415–420. PMID: 16970954

28. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989 Apr 6; 320(14):904–910. PMID: 2619783

29. Leppala JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP. Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke 1999 Dec; 30(12):2535–2540. PMID: 10582974

30. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004 Nov 23; 63 (10):1866–1875. PMID: 15557504

31. Kettunen J, Tukkainen T, Sarin AP, Ortega-Alonso A, Tikkanen E, Lyytikainen LP, et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet 2012 Jan 29; 44(3):269–276. doi: 10.1038/ng.1073 PMID: 22286219

32. Hill AB. The Environment and Disease: Association Or Causation? Proc R Soc Med 1965 May; 58:295–300. PMID: 14283879

33. Frosen J, Tulamo R, Paetau A, Laaksamo E, Korja M, Laakso A, et al. Saccular intracranial aneurysm: pathology and mechanisms. Acta Neuropathol 2012 Jun; 12; 123(6):773–786. doi: 10.1007/s00401-011-0939-3 PMID: 22249619

34. World Health Organization. Description of the global burden of NCDs, their risk factors and determinants. Global status report on noncommunicable diseases 2011 1–176.

35. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011 Feb 12; 377(9765):578–586. doi: 10.1016/S0140-6736(10)60238-7 PMID: 21295847

36. Haase CL, Tybjaerg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab 2012 Feb; 97(2):E248–56. doi: 10.1210/jc.2011-1846 PMID: 22090275

37. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 2015 Mar 1; 36(9):539–550. doi: 10.1093/eurheartj/ehu571 PMID: 24474739

38. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012 Aug 11; 380(9841):572–580. doi: 10.1016/S0140-6736(12)60312-2 PMID: 22607825

39. Evangelista O, McLaughlin MA. Review of cardiovascular risk factors in women. Gend Med 2009; 6 Suppl 1:17–36. doi: 10.1016/j.gmen.2009.02.004 PMID: 19318217

40. Tan YY, Gast GC, van der Schouw YT. Gender differences in risk factors for coronary heart disease. Maturitas 2010 Feb; 65(2):149–160. doi: 10.1016/j.maturitas.2009.09.023 PMID: 19897327

41. Auro K, Joensuu A, Fischer K, Kettunen J, Salo P, Mattsson H, et al. A metabolic view on menopause and ageing. Nat Commun 2014 Aug 5; 5:4708. doi: 10.1038/ncomms5708 PMID: 25144627

42. Korja M, Silventoinen K, Laittikainen T, Joussilahti P, Salomaa V, Kaprio J. Cause-specific mortality of 1-year survivors of subarachnoid hemorrhage. Neurology 2013 Jan 29; 80(5):481–486. doi: 10.1212/WNL.0b013e31827f0fb5 PMID: 23303843

43. Bekelis K, Smith J, Zhou W, MacKenzie TA, Roberts DW, Skinner J, et al. Statins and subarachnoid hemorrhage in Medicare patients with unruptured cerebral aneurysms. Int J Stroke 2015 Oct; 10 Suppl A100:38–45. doi: 10.1111/ijs.12559 PMID: 26120925

44. Borodulin K, Vartiainen E, Peltonen M, Joussilahti P, Juolevi A, Laittikainen T, et al. Forty-year trends in cardiovascular risk factors in Finland. Eur J Public Health 2015 Jun; 25(3):539–546. doi: 10.1093/eurpub/cku174 PMID: 25422363
45. Aull S, Lalouschek W, Schnider P, Sinzinger H, Uhl F, Zeiler K. Dynamic changes of plasma lipids and lipoproteins in patients after transient ischemic attack or minor stroke. Am J Med 1996 Sep; 101 (3):291–298. PMID: 8873491

46. Woo J, Lam CW, Kay R, Wong HY, Teoh R, Nicholls MG. Acute and long-term changes in serum lipids after acute stroke. Stroke 1990 Oct; 21(10):1407–1411. PMID: 2219204